- R&D Pipeline
- Season 2 (2021-2030)
| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | A study on derivation and optimization of non-clinical candidates for nonalcoholic steatohepatitis gene therapy | ||||||
| Gene Therapy | NASH | CR-P1 | Candidate | Curogen Technology | HN21C0805 | ||
| 2 | Fat-targeting non-viral gene therapeutics for the treatment of obesity and obesity-induced metabolic syndrome | ||||||
| Gene Therapy | Obesity | FABP4, FABP5 | Lead | Hanyang University | HN21C0885 | ||
| 3 | Research on lead optimization of miRNA-based therapeutics for treatment of sarcopenia | ||||||
| Gene Therapy | Sarcopenia | Atrogin-1 | Lead | Aventi Inc. | HN21C0500 | ||